Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer.

Ironwood Pharmaceuticals, Inc.’s IRWD share price has dipped by 5.28%, which has investors questioning if this is right time to buy.

BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ETCompany ParticipantsJeff Stewart - EVP and Chief ...

(Reuters) -The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who ...

The siRNA technology has has the potential to enable sustained and precise messenger RNA silencing, regulating the expression ...

Workers at AbbVie’s manufacturing facility in Carrigtwohill, Ireland—one of six plants the Illinois drugmaker runs in the ...